Efficacy and safety of dabigatran in cirrhosis with chronic portal vein thrombosis: A randomized, placebo-controlled double-blind trial (DAB-PVT).

医学 达比加群 肝硬化 安慰剂 门静脉血栓形成 内科学 临床终点 腹水 胃肠病学 外科 临床试验 血栓形成 随机对照试验 门脉高压 慢性肝病 不利影响 静脉 门静脉 静脉曲张 肝病
作者
Babu Lal Meena,Srinivasa Reddy Golamari,Ankit Bhardwaj,Ankur Jindal,Rajan Vijayaraghavan,Vinod Arora,Shalini Thapar Laroia,Amar Mukund,Guresh Kumar,Shiv Kumar Sarin
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
标识
DOI:10.14309/ajg.0000000000004254
摘要

INTRODUCTION: Direct oral anticoagulants (DOACs) are emerging options for portal vein thrombosis (PVT) in cirrhosis, though their safety and efficacy remain uncertain. We evaluated the efficacy and safety of dabigatran for PVT recanalization. METHODS: Eighty-four patients with cirrhosis and PVT were prospectively randomized to receive dabigatran(n=42; 150 mg twice daily) or placebo(n=42) for 12 months. The primary endpoint was complete recanalization(CR) of the portal vein at 12 months. Secondary endpoints included safety, clinical outcomes, and changes in the liver disease severity scores and mortality. RESULTS: Patients were predominantly male(71.4%), with a mean age of 48.5± 9.1 years and median Child-Turcotte-Pugh(CTP) score of 8(7-8). Medium-to-large varices were present in 60.7%, prior variceal bleeding in 45.2%, and ascites in 54.8%. At 12 months, complete recanalization occurred in 27/42(64.3%) in dabigatran group compared to 9/42(21.4%) in the placebo group(p<0.001). On multivariable Cox regression, dabigatran treatment was independently associated with complete recanalization (adjusted HR, 4.35; 95% CI, 2.03-9.36; P<0.001), along with a more favorable baseline ALBI score (adjusted HR, 2.02; 95% CI, 1.02-4.01; P=0.044). Variceal bleeding episodes were less frequent with dabigatran (3 vs. 12; p = 0.008). Compared with placebo, patients receiving dabigatran showed greater improvement in CTP scores (ΔCTP -0.57 ± 1.17 vs. 0.19 ± 1.17; P=0.004) and ALBI scores (ΔALBI -0.29 ± 0.82 vs. 0.06 ± 0.49; P=0.020). Longitudinal mixed-effects analysis demonstrated significantly different trajectories for CTP and ALBI scores, whereas MELD trajectories were comparable between groups. CONCLUSION: In patients with Child-Pugh A/B cirrhosis and chronic PVT, dabigatran significantly increased complete portal vein recanalization compared with placebo with fewer bleeding events. The observed differences in clinical events and liver disease severity scores could be considered exploratory requiring evaluation in larger comparative studies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zyyys发布了新的文献求助10
刚刚
1秒前
1秒前
Tylose发布了新的文献求助10
1秒前
CipherSage的应助被只是听说采纳,获得10
1秒前
xushanqi发布了新的文献求助10
2秒前
2秒前
zyp发布了新的文献求助10
2秒前
2秒前
彭于彦祖的应助被珍珠采纳,获得30
2秒前
CodeCraft的应助被珍珠采纳,获得30
2秒前
2秒前
汉堡包的应助被调皮钧采纳,获得10
3秒前
3秒前
3秒前
知予完成签到 ,获得积分10
3秒前
难过的元容完成签到,获得积分10
4秒前
4秒前
东方鸾完成签到,获得积分10
5秒前
hualuo13完成签到,获得积分10
5秒前
5秒前
sinmon完成签到,获得积分10
5秒前
5秒前
晴天完成签到,获得积分10
5秒前
kss完成签到,获得积分10
6秒前
6秒前
呆呆发布了新的文献求助10
7秒前
7秒前
7秒前
嘻嘻哈哈的应助被zyyys采纳,获得10
7秒前
7秒前
8秒前
dongshao2027完成签到,获得积分10
8秒前
陈zero完成签到,获得积分10
8秒前
9秒前
科研通AI6.3的应助被kuku采纳,获得30
9秒前
9秒前
池恩完成签到,获得积分10
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180807
求助须知:如何正确求助?哪些是违规求助? 9570895
关于积分的说明 21815089
捐赠科研通 7777155
什么是DOI,文献DOI怎么找? 3433347
关于科研通互助平台的介绍 2557613
邀请新用户注册赠送积分活动 2479317